However, in recent gastric cancer research, studies have demonstrated that targeting both PDGFRA and PDGFRB in the tumor stroma can reverse the immunosuppressive microenvironment, leading to improved effectiveness of immune checkpoint inhibitors (ICIs) [33]. This evidence concerns the gene PDGFRA and gastric cancer.